Viewing offline content

Limited functionality available

Dismiss
United States
  • Services

    What's New

    • Register for Dbriefs webcasts

    • Unlimited Reality™

      Metaverse solutions that drive value

    • Sustainability, Climate & Equity

      Cultivating a sustainable and prosperous future

    • Tax

      • Tax Operate
      • Tax Legislation
      • Tax Technology Consulting
      • Mobility and Payroll
      • Legal Business Services
      • Tax Services
    • Consulting

      • Core Business Operations
      • Customer & Marketing
      • Enterprise Technology & Performance
      • Human Capital
      • Strategy & Analytics
    • Audit & Assurance

      • Audit Innovation
      • Accounting Standards
      • Accounting Events & Transactions
    • Deloitte Private

    • M&A and Restructuring

    • Risk & Financial Advisory

      • Accounting & Internal Controls
      • Cyber & Strategic Risk
      • Regulatory & Legal
      • Transactions and M&A
    • AI & Analytics

    • Cloud

    • Diversity, Equity & Inclusion

  • Industries

    What's New

    • The Ripple Effect

      Real-world client stories of purpose and impact

    • Register for Dbriefs webcasts

    • Industry Outlooks

      Key opportunities, trends, and challenges

    • Consumer

      • Automotive
      • Consumer Products
      • Retail, Wholesale & Distribution
      • Transportation, Hospitality & Services
    • Energy, Resources & Industrials

      • Industrial Products & Construction
      • Power, Utilities & Renewables
      • Energy & Chemicals
      • Mining & Metals
    • Financial Services

      • Banking & Capital Markets
      • Insurance
      • Investment Management
      • Real Estate
    • Government & Public Services

      • Defense, Security & Justice
      • Federal health
      • Civil
      • State & Local
      • Higher Education
    • Life Sciences & Health Care

      • Health Care
      • Life Sciences
    • Technology, Media & Telecommunications

      • Technology
      • Telecommunications, Media & Entertainment
  • Insights

    Deloitte Insights

    What's New

    • Deloitte Insights Magazine

      Explore the latest issue now

    • Deloitte Insights app

      Go straight to smart with daily updates on your mobile device

    • Weekly economic update

      See what's happening this week and the impact on your business

    • Strategy

      • Business Strategy & Growth
      • Digital Transformation
      • Governance & Board
      • Innovation
      • Marketing & Sales
      • Private Enterprise
    • Economy & Society

      • Economy
      • Environmental, Social, & Governance
      • Health Equity
      • Trust
      • Mobility
    • Organization

      • Operations
      • Finance & Tax
      • Risk & Regulation
      • Supply Chain
      • Smart Manufacturing
    • People

      • Leadership
      • Talent & Work
      • Diversity, Equity, & Inclusion
    • Technology

      • Data & Analytics
      • Emerging Technologies
      • Technology Management
    • Industries

      • Consumer
      • Energy, Resources, & Industrials
      • Financial Services
      • Government & Public Services
      • Life Sciences & Health Care
      • Technology, Media, & Telecommunications
    • Spotlight

      • Deloitte Insights Magazine
      • Press Room Podcasts
      • Weekly Economic Update
      • COVID-19
      • Resilience
      • Top 10 reading guide
  • Careers

    What's New

    • Our Purpose

      Exceptional organizations are led by a purpose. At Deloitte, our purpose is to make an impact that matters by creating trust and confidence in a more equitable society.

    • Day in the Life: Our hybrid workplace model

      See how we connect, collaborate, and drive impact across various locations.

    • The Deloitte University Experience

      Explore Deloitte University like never before through a cinematic movie trailer and films of popular locations throughout Deloitte University.

    • Careers

      • Audit & Assurance
      • Consulting
      • Risk & Financial Advisory
      • Tax
      • Internal Services
      • US Delivery Center
    • Students

      • Undergraduate
      • Advanced Degree
      • Internships
    • Experienced Professionals

      • Additional Opportunities
      • Veterans
      • Industries
      • Executives
    • Job Search

      • Entry Level Jobs
      • Experienced Professional Jobs
      • Recruiting Tips
      • Explore Your Fit
      • Labor Condition Applications
    • Life at Deloitte

      • Life at Deloitte Blog
      • Meet Our People
      • Diversity, Equity, & Inclusion
      • Corporate Citizenship
      • Leadership Development
      • Empowered Well-Being
      • Deloitte University
    • Alumni Relations

      • Update Your Information
      • Events
      • Career Development Support
      • Marketplace Jobs Dashboard
      • Alumni Resources
  • US-EN Location: United States-English  
  • Contact us
  • US-EN Location: United States-English  
  • Contact us
    • Dashboard
    • Saved items
    • Content feed
    • Subscriptions
    • Profile/Interests
    • Account settings

Welcome back

Still not a member? Join My Deloitte

Agile responses to China’s health care transformation

by David Xie, Xiaofeng Li, An Li
  • Save for later
  • Download
  • Share
    • Share on Facebook
    • Share on Twitter
    • Share on Linkedin
    • Share by email
Deloitte Insights
  • Strategy
    Strategy
    Strategy
    • Business Strategy & Growth
    • Digital Transformation
    • Governance & Board
    • Innovation
    • Marketing & Sales
    • Private Enterprise
  • Economy & Society
    Economy & Society
    Economy & Society
    • Economy
    • Environmental, Social, & Governance
    • Health Equity
    • Trust
    • Mobility
  • Organization
    Organization
    Organization
    • Operations
    • Finance & Tax
    • Risk & Regulation
    • Supply Chain
    • Smart Manufacturing
  • People
    People
    People
    • Leadership
    • Talent & Work
    • Diversity, Equity, & Inclusion
  • Technology
    Technology
    Technology
    • Data & Analytics
    • Emerging Technologies
    • Technology Management
  • Industries
    Industries
    Industries
    • Consumer
    • Energy, Resources, & Industrials
    • Financial Services
    • Government & Public Services
    • Life Sciences & Health Care
    • Tech, Media, & Telecom
  • Spotlight
    Spotlight
    Spotlight
    • Deloitte Insights Magazine
    • Press Room Podcasts
    • Weekly Economic Update
    • COVID-19
    • Resilience
    • Top 10 reading guide
    • US-EN Location: United States-English  
    • Contact us
      • Dashboard
      • Saved items
      • Content feed
      • Subscriptions
      • Profile/Interests
      • Account settings
    5 minute read 18 April 2019

    Agile responses to China’s health care transformation Launching innovative biopharma in China

    5 minute read 18 April 2019
    • David Xie China
    • Xiaofeng Li United Kingdom
    • An Li United Kingdom
    • Save for later
    • Download
    • Share
      • Share on Facebook
      • Share on Twitter
      • Share on Linkedin
      • Share by email
    • 1. Manage uncertainties efficiently
    • 2. Empower internal teams
    • 3. Build a rapid decision and learning cycle
    • 4. Explore external partnerships
    • Conclusion

    ​In this final article of a four-part series, Deloitte writes a reality check regarding China’s shape-shifting health care environment. Are you as agile as you could be for your next launch to excel?

    The media rarely allow us to forget the trade wars taking place between the US and China, and biopharma companies looking to launch innovative products in China are, no doubt, anxiously monitoring that situation. But what may be escaping your attention are the less overt tremors rippling throughout the industry, which should matter just as much – if not more: China’s deepening health care

    Learn More

    Explore the Launching innovative biopharma in China series

    View the Life Sciences collection

    Subscribe to receive more information about innovative biopharma in China

    reform with a growing tiered system, the many budding innovative Chinese newcomers (as of 2018, more than 130 Class I domestic pipeline products were registering or in Phase 3), and changing payers at the sub-regional and hospital levels, as well as in the private sector.

    Having just one area of uncertainty could easily affect all aspects of a biopharma company, not to mention a specific product launch strategy, in China. As depicted in Figure 1, the changes are rapid and transformational, and they bring challenges. Biopharma companies need to establish a system that comprises agile methods and a China-centric perspective, to keep afloat on the sea of change, but also to succeed.

    Major recent health care reform events in China (non-exhaustive)

    In Deloitte’s experience, many multinational companies have not yet established an internal structure or systematic launch framework that permits an agile approach to China. They apply a generalised planning approach and key performance index, then encounter difficulties when unexpected market events take place. For a successful launch of an innovative product in China, most biopharma companies need to make the four big changes shown in Figure 2.

    Key shifts required to achieve launch excellence in China's rapidly changing environment

    Many companies may think they are meeting the challenges China is throwing at the industry, but they may not be acknowledging the common problems outlined below. There are a lot of ways to build resilience, and help turn what could be a perfectly adequate product launch into a winning one.

    1. Manage uncertainties efficiently

    Typical problem: There are too many uncertainties and your launch team struggles to plan around the full range of them. By expending so much energy trying to identify all the potential risks and future scenarios, you cannot form the ability to make good decisions in the face of uncertainty.

    Solutions:

    • Senior leaders need to understand the overall industry trends for the business, but become especially familiar with general policy direction, rather than creating detailed plans for individual changes or policy updates. Being able to grasp where the market is heading, and using it to guide an efficient, overarching launch strategy, is critical.

    • Global and local product launch teams should work closely together to build a scenario-based framework. Good scenarios challenge the key assumptions that underpin the baseline view, allowing you to peer around the corner at alternative versions of the future. You should:

      • prioritise uncertainties based on probability and impact
      • feed them into various scenarios and pilot simulation exercises
      • analyse the scenarios, including their impact on brand performance
      • practise flexibility in considering the various outcomes, and make necessary adjustments accordingly.

    2. Empower internal teams

    Typical problem: Organisational bureaucracy in decision making is preventing your products from achieving the ideal launch. A restrictive hierarchy can happen at the global/country level, or within China, or even among various teams. What’s more, outdated company processes are burdened with legacy thinking and systems. All these factors contribute to poor timing of decisions and reactions to the changing market space.

    Solutions:

    • Establish dedicated functions or ‘SWAT’ teams with more resources and ownership of ultimate decisions. With a flexible structure and agile way of working, they can respond to changes and explore bold or new product launch ideas in China’s dynamic health care environment.

    • Build a quick course-correction mechanism. With historically limited real-life insights, and an inflexible commercial model, it can be impossible to monitor performance dynamically and make course corrections.1 Establish a way to minimise risk while you embrace uncertainty – that way, if you fail, you can fail fast and then change tack.

    • Implement flexible key performance indicators (KPIs) for the ‘SWAT’ teams, as well as other functions, such as finance and compliance. This will unlock value by allowing teams to pivot around disadvantageous situations, or be more malleable in product launches and enable quick reactions to business needs.

    3. Build a rapid decision and learning cycle

    Typical problem: Your launch activities in China are repeatedly hampered by a fixed planning cycle (annual/quarterly), whose timing is not in line with significant market events. This rigidity leads to conflicts between global and country teams when it comes to overall KPIs and planning.

    Solutions:

    • Align the strategies of global and local teams with each other early on, ensuring they are allowed flexible collaboration to make the smartest choices for a specific launch. And remember that a culture shift is required for non-Chinese teams to work with any Chinese team.

    • Establish a mechanism that allows in-country feedback and adjustments to deal with unexpected product launch outcomes. For example, any significant local insights collected by the sales team would reach your branding lead efficiently. Give local teams clear responsibility and authority, and encourage more autonomy in staff.

    4. Explore external partnerships

    Typical problem: Your organisation responds slowly to changes because there is not sufficient capability to deal with everything in the product launch process. But you are wary of building partnerships, seeing them as transactional and carrying risks.

    Solutions:

    • Build your agility by entering partnerships that can enhance your capabilities in terms of data and service. Many Chinese vendors/partners can offer an in-depth understanding of the local markets, expertise in a special field, and their own resources and channels to go to market.2 Take, for example, Ali Health: a subsidiary of the tech giant Alibaba Group that has strong technology capabilities and wide customer reach. Recently, a big biopharma company partnered with Ali Health to take advantage of these capabilities, delivering new smart health services that aim to help patients find and stay on the right medicines.3 By reaping a partner’s benefits, you can engage in outcomes-based contracting, better understand how therapies are used and improve patient outcomes.

    • Work around the tightening restrictions on your sales team by embracing alternatives. Those companies that have invested in digital partnerships have found value in them already, given the limitations being placed on sales representatives.

    • Foster dynamic partnerships through strategic alignment of both parties, a close working culture, good communication between internal and external stakeholders, and a dedicated project team that can have some autonomy and agility to ensure successful execution.

    Examples of partnerships that allow for cultural adaption, local market understanding and improved patient outcome

    Conclusion

    Being aware of the rapid-fire changes shaking up China’s health care environment is simply not enough these days. The changes demand that biopharma companies look hard at their approach to uncertainties, team empowerment, adroit decision making and smart collaboration with partners. The successful product launch is one that reflects agility at a programme and enterprise level, and the bonus is the introduction – or reintroduction – of speed, flexibility, customer focus and continuous improvement to the core of your company.

    Explore further insights into launching innovative biopharmaceuticals in China with three other articles in this series, on: market access and reimbursement, digital technologies and regulations.

     

    Acknowledgments

    Cover image by: Mike Ellis

    Endnotes
      1. Winning launches: using analytics and creativity to create superior share of insight, McKinsey & Company, June 2012. View in article

      2. Zhejiang Health Planning Commission and Ali Strategic Cooperation Explore Internet and New Medical Model, Xinhua News, 16 May 2017. View in article

      3. AstraZeneca links with Alibaba and Tencent in China push, Thomson Reuters, 2 February 2018. View in article

    Show moreShow less

    Topics in this article

    China , Pharmaceutical , Life Sciences & Health Care

    LSHC China

    The LSHC team at Deloitte Consulting China supports a multitude of product launches every year. We help our clients prioritize launch assets based on a holistic assessment of external and internal attractiveness factors. Our insights into rapidly changing regulatory policies allow for clinical and regulatory affairs organizations to make informed decisions within accurate regulatory paths when bringing assets to China. We help commercial organizations to develop impactful brand strategy leveraging our industry-leading market excellence methodology and commercial innovation framework, activated by a large network of KOLs and patient organizations. We are also the leader in end-to-end market access planning, including scenario based access strategy, TA level HEOR analytics, as well design and implementation of specific access models and more innovative access contracts.

    Learn more
    Get in touch
    Contact
    • Andrew Yu
    • Deloitte China Life Sciences & Health Care Consulting Leader, Managing Partner
    • Deloitte China
    • andryu@deloitte.com.cn
    • +86 21 23166913

    Download Subscribe

    Related content

    img Trending

    Interactive 3 days ago

    Explore the series Launching innovative biopharma in China

    • Gain the edge in a fast-moving market Article3 years ago
    • A new view on biopharma market access in China Article3 years ago
    • A new view on China’s digital health care Article3 years ago
    • Optimizing biopharma market access Article3 years ago
    • Survey finds biopharma companies lag in digital transformation Article4 years ago
    • Invigorating biopharma Article8 years ago
    David Xie

    David Xie

    David is a director based in Deloitte’s Shanghai office. David has extensive R&D operations and strategy consulting experience. In his consulting career, David worked with various clients from the pharmaceutical, provider, private equity and not-for-profit fields, focusing on strategy and innovation projects as well as market access and organisational transformation, private equity investments and global health delivery.

    • daxie@deloitte.com.cn
    • +862161411209
    Xiaofeng Li

    Xiaofeng Li

    Li is a manager at Deloitte's Strategy Consulting practice and specialises in the life sciences and health care industry, focusing on commercial and clinical development as well as corporate strategy. He brings in-depth knowledge of health care systems in global markets as well as a high level of experience in delivering insights and solutions for a variety of complex strategic issues over a broad range of therapeutic areas.

    • xiaofli@deloitte.co.uk
    • +442070073042
    An Li

    An Li

    An Li is an analyst with Deloitte’s Technology Consulting practice specialising in the life sciences and health care industry and focusing on real-world evidence, digital health care partnerships, and corporate strategy. An’s academic research experience additionally equips her with in-depth knowledge of health care systems in global markets.

    • anxli@deloitte.co.uk

    Share article highlights

    See something interesting? Simply select text and choose how to share it:

    Email a customized link that shows your highlighted text.
    Copy a customized link that shows your highlighted text.
    Copy your highlighted text.

    Agile responses to China’s health care transformation has been saved

    Agile responses to China’s health care transformation has been removed

    An Article Titled Agile responses to China’s health care transformation already exists in Saved items

    Invalid special characters found 
    Forgot password

    To stay logged in, change your functional cookie settings.

    OR

    Social login not available on Microsoft Edge browser at this time.

    Connect Accounts

    Connect your social accounts

    This is the first time you have logged in with a social network.

    You have previously logged in with a different account. To link your accounts, please re-authenticate.

    Log in with an existing social network:

    To connect with your existing account, please enter your password:

    OR

    Log in with an existing site account:

    To connect with your existing account, please enter your password:

    Forgot password

    Subscribe

    to receive more business insights, analysis, and perspectives from Deloitte Insights
    ✓ Link copied to clipboard
    • Contact us
    • Search jobs
    • Submit RFP
    • Subscribe to Deloitte Insights
    Follow Deloitte Insights:
    Global office directory US office locations
    US-EN Location: United States-English  
    About Deloitte
    • About Deloitte
    • Client stories
    • My Deloitte
    • Deloitte Insights
    • Email subscriptions
    • Press releases
    • Submit RFP
    • US office locations
    • Alumni
    • Global office directory
    • Newsroom
    • Dbriefs webcasts
    • Contact us
    Services
    • Tax
    • Consulting
    • Audit & Assurance
    • Deloitte Private
    • M&A and Restructuring
    • Risk & Financial Advisory
    • AI & Analytics
    • Cloud
    • Diversity, Equity & Inclusion
    Industries
    • Consumer
    • Energy, Resources & Industrials
    • Financial Services
    • Government & Public Services
    • Life Sciences & Health Care
    • Technology, Media & Telecommunications
    Careers
    • Careers
    • Students
    • Experienced Professionals
    • Job Search
    • Life at Deloitte
    • Alumni Relations
    • About Deloitte
    • Terms of Use
    • Privacy
    • Privacy Shield
    • Cookies
    • Cookie Settings
    • Legal Information for Job Seekers
    • Labor Condition Applications
    • Do Not Sell My Personal Information

    © 2023. See Terms of Use for more information.

    Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

    Learn more about Deloitte's work for the US Olympic Committee